EASEE is Precisis' neurostimulation device that can act in two modes - excitatory and inhibitory. The duality of the device allows its to be used for the treatment of many cerebral diseases, including epilepsy, depression, and cognitive disfunctions caused by stroke. Precisis is currently developing a close-loop system for their EASEE technology, which will allow the device to record brain activity and respond with targeted stimulation. Visit website.

Precision Cardiovascular is focused on enhancing the outcomes and quality of life for patients with heart failure. The company is developing a miniature sensor that is placed in the pulmonary artery to continuously collect and analyze data to improve the remote management of cardiovascular diseases. Visit website.

Novel medical devices to enhance the reliability and safety of orthopedics procedures.  Visit website.

Arsenal Medical develops innovative biomaterials to solve challenging and underserved medical problems. Our lead products target neurovascular and trauma conditions providing control of blood flow to tumors and bleeding conditions, such as hemorrhage.  Visit website.

IQ Endoscopes develops single-use flexible endoscopes designed to address challenges associated with traditional reusable scopes. Their devices aim to reduce the risks of cross-contamination and eliminate the need for complex reprocessing. The company’s first-generation gastroscope, the Q Vision G-100, has received both FDA 510(k) clearance and UKCA approval. IQ Endoscopes is working towards expanding its product range to include additional gastrointestinal endoscopes by 2025. Visit website.

H2 Global Group is a pioneer in using molecular hydrogen in the fields of healthcare (including biotech and medtech), wellness, beauty, and veterinary medicine with patented solution for Alzheimer disease. Visit website.

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics. Visit website.

Happitech has developed a CE-marked, smartphone-based method for effective remote monitoring of patients. The company's core competencies in artificial intelligence (AI) integration and photoplethysmography (PPG) enable effective and accurate measurement of heart rate and atrial fibrillation. Visit website.

GuideAI Health automates the early detection of peripheral vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts from IBM Watson Health. The platform addresses the 90% miss rate in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision.  Visit website.

EP Solutions is improving clinical outcomes in cardiac resynchronization therapy cases through the use of noninvasive cardiac mapping technology. The company's Amycard 01C is an electrophysiology workstation that records body surface electrograms to create optimized 3D heart models that merge ECG data with anatomical data obtained from medical imaging. EP Solutions' technology helps physicians accurately place CRT leads during implantation and optimize devices during follow-up visits. Visit website.

Cultivating brain health therapy through continuous, ultra-long-term EEG monitoring and transformative real-world data. Our MDR CE-approved 24/7 EEG SubQ solution captures subcutaneous brain activity to deliver actionable insights that empower clinicians and researchers to personalize treatment and reduce uncontrolled seizures in epilepsy. By harnessing AI and big data, we are unlocking new possibilities in digital biomarkers, drug development, and neuromodulation. Visit website.

ART MEDICAL develops the smART+ Platform to address malnutrition and reduce the risk of ventilator-associated pneumonia in intensive care units. The platform offers features that enhance staff productivity and enable precise, data-driven care. Clinically proven to reduce ICU stays and ventilation duration by 3.3 days, smART+ achieves up to 100% feeding efficiency through real-time reflux detection, dynamic nutritional compensation, and continuous tube positioning monitoring. Visit website.

Life Seal Vascular is developing an aneurysm sac management technology designed to reduce the incidence of Type II endoleaks following Endovascular Aneurysm Repair (EVAR). Type II endoleaks are the leading cause of reintervention after EVAR, and the Life Seal device is compatible with all EVAR systems. Currently in the pre-clinical stage, the company anticipates achieving First In Man (FIM) in Q2 of 2025. Visit website.

Vena Vitals is an early stage med-tech company focused on non-invasive continuous blood pressure monitoring. The company's proprietary technology is a soft flexible sensor that conforms to the skin for direct pressure measurement at theradial artery. The company's technology is intended to replace unnecessarily invasive arterial line measurements as well as non-continuous cuff-based methods in both the hospital and at home. Visit website.

Sequana Medical NV develops technologies to treat diuretic-resistant fluid overload in liver disease, heart failure, and cancer. Its alfapump device, approved by the FDA as a breakthrough and PMA-approved, is a fully implantable pump that automatically moves excess fluid to the bladder for natural excretion, targeting recurrent ascites from liver cirrhosis. Sequana Medical is also advancing DSR, a phase IIa drug program aimed at treating diuretic resistance and cardiorenal syndrome in heart failure. Both technologies address large and growing markets driven by increasing disease prevalence. Visit website.

Rekovar develops wearable biosensor technology aimed at improving the management of Neonatal Abstinence Syndrome (NAS). Its flagship product, NeoMonki, is an investigational neonatal monitoring kit designed to provide real-time, objective data on infants' physiological and behavioral states. The system includes a wristband sensor, imaging camera, tablet application, and a provider portal, enabling healthcare professionals to deliver personalized care and intervention. Visit website.

Plexāā is a UK-based MedTech company developing innovative solutions to improve surgical outcomes. Its flagship device, BLOOM⁴³, is a fully wearable system designed to precondition the skin before breast surgery by gently warming the area to stimulate the release of Heat Shock Proteins, which improve blood flow and support healing. Clinical trials have shown that this approach can reduce wound healing complications such as infection and skin necrosis. Plexāā is also investigating applications of this technology in other surgical areas including obstetrics, orthopedics, and vascular surgery. Visit website.

Nitinotes develops the EndoZip™, the first fully automated endoscopic suturing system for Endoscopic Sleeve Gastroplasty (ESG), a minimally invasive weight-loss procedure. Designed for efficiency, EndoZip enables a single-operator ESG procedure with automated, standardized suturing, reducing variability, procedure time, and training requirements. The system facilitates outpatient treatment with low-risk and predictable outcomes, addressing the growing need for effective, non-surgical obesity interventions. Visit website.

Cresilon is a biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company’s proprietary hydrogel technology. The company’s plant-based technology has revolutionized the current standard by stopping bleeding in seconds. The company’s current and future product lines target trauma care, biosurgery, and animal health.  Visit website.

Sonion Health is developing a biosensing digital health platform for cuffless blood pressure monitoring, addressing hypertension as a major risk factor for cardiovascular mortality. The technology has been developed over several years by Sonion engineers, known for their expertise in balanced armature receivers, premium microphones, and electromechanical devices. This platform aims to enhance hypertension management through continuous, non-invasive monitoring.

Acuamark Diagnostics is optimizing qPCR and dPCR for early cancer detection and cancer recurrence. Its approach is designed to provide highly accurate results to physicians and patients at a fraction of the cost per life saved. With market leading clinical results in stage 1-4 colorectal cancer, Acuamark is currently developing diagnostics for multiple cancers. US launch of its first products is estimated in 2026.  Visit website.

NeoCor develops the CoApt Valve®, a transcatheter device designed to treat severe mitral and tricuspid valve disease through a minimally invasive approach. The CoApt Valve features a self-expanding nitinol frame and an electrospun polymeric valve, aiming to reduce or eliminate regurgitant jets without the need for open-heart surgery. The device is delivered via a catheter inserted through the transfemoral vein, preserving the native valve structure. CoApt Valve is advancing its technology through preclinical studies in both canine and human models, with plans to initiate veterinary clinical trials.​ Visit website.

TYBR Health is developing a natural hydrogel to prevent adhesions (internal scarring) that can occur following minimally invasive surgery. The technology is intended to reduce post-operative complications which can cause patients pain and require rehabilitation following tendon and joint surgeries.  Visit website.

VirtaMed develops mixed-reality surgical simulators designed to enhance medical education and improve patient outcomes. Its platforms integrate real surgical instruments with haptic feedback and photorealistic graphics to provide immersive training experiences across specialties such as orthopedics, obstetrics and gynecology, urology, and general surgery. VirtaMed also offers customizable training solutions for medical device companies and educational institutions, supported by its cloud-based platform, VirtaMed Connect, for performance tracking and curriculum development. The company is headquartered in Zurich, Switzerland, with additional locations in the United States and China. Visit website.